Researches and develops cannabinoid-based therapies for various diseases. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 635% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 635% a year on average.
The company sells $3.2B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 44 buys and 5 sells. Management buying with its own money is usually read as a good sign.
A loss of $1.2B against $3.2B in annual sales.
At the current pace of spending, the cash lasts about 1.9 years. After that, the company needs to find new money.
On our five-subject report card, INM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: INM has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.